ArticleLeukemia research2019

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.

Amber C King et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.